Royal Bank of Canada’s GSK GSK Stock Holding History

Royal Bank of Canada’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,920	Closed	-$100K	–	6977
2019 Q1	$100K	Buy	1,920 +1,600	+500%	+$80K	﹤0.01%	4773
2018 Q4	$15K	Buy	+320	New	+$15.8K	﹤0.01%	5702
2017 Q3	–	Sell	-160	Closed	-$9K	–	6797
2017 Q2	$9K	Sell	160 -18,880	-99%	-$1.01M	﹤0.01%	5839
2017 Q1	$1M	Sell	19,040 -960	-5%	-$48.7K	﹤0.01%	3085
2016 Q4	$963K	Buy	20,000 +18,560	+1,289%	+$917K	﹤0.01%	3187
2016 Q3	$78K	Buy	1,440 +400	+38%	+$21.9K	﹤0.01%	4925
2016 Q2	$56K	Hold	1,040	–	–	﹤0.01%	5066
2016 Q1	$53K	Buy	+1,040	New	+$51.8K	﹤0.01%	5099
2015 Q4	–	Sell	-13,520	Closed	-$650K	–	6713
2015 Q3	$650K	Buy	13,520 +6,400	+90%	+$333K	﹤0.01%	3247
2015 Q2	$371K	Buy	+7,120	New	+$401K	﹤0.01%	3887
2015 Q1	–	Sell	-40,000	Closed	-$2.14M	–	6245
2014 Q4	$2.14M	Hold	40,000	–	–	﹤0.01%	2289
2014 Q3	$2.3M	Hold	40,000	–	–	﹤0.01%	2196
2014 Q2	$2.67M	Hold	40,000	–	–	﹤0.01%	2076
2014 Q1	$2.67M	Buy	+40,000	New	+$2.7M	﹤0.01%	2041

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada's GSK Position: Q1 2026 in Review

Royal Bank of Canada reduced its GSK (GSK) stake by 11% in Q1 2026, selling an estimated $52.8M and leaving 7,506,786 shares worth $414M. The position accounts for 0.07% of the portfolio, ranked #251.

Royal Bank of Canada first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $958M in Q4 2013. 1,034 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Royal Bank of Canada held 7,506,786 shares of GSK worth $414M as of Q1 2026.
Royal Bank of Canada sold 973,760 GSK shares in Q1 2026, an estimated $52.8M.
GSK made up 0.07% of Royal Bank of Canada's portfolio in Q1 2026, its #251 holding.
Royal Bank of Canada first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's GSK position peaked at $958M in Q4 2013.
1,034 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.